Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q1 2025 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2024 Net Income-$14.88M-$14.88MN/M vs Q1 2024 EPS Diluted-$0.17-$0.17N/M vs Q1 2024 Operating Income-$15,773,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
Free Cash Flowderived-$15,420,000N/M ended Mar 31, 2025 · filed May 7, 2025 · 37 d after period end